Notably missing from everyone's fat burner list seems to be SS forskolin. Human data trumps most of these other ingredients!
If you read the full text of the first study I posted, the loss of actual fat mass was 900% greater in forskolin-treated men relative to controls. The rate of weight loss in a 12-week period is a hair below the clinically observed weight loss that ECA during a 12-week period would elicit.
Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men.
Godard MP,
Johnson BA,
Richmond SR.
Source
University of Kansas, Department of Health, Sport and Exercise Sciences, Applied Physiology Laboratory, Lawrence, KS 66045, USA.
[email protected]
Abstract
OBJECTIVE:
This study examined the effect of forskolin on body composition, testosterone, metabolic rate, and blood pressure in overweight and obese (BMI > or = 26 kg/m(2)) men.
RESEARCH METHODS AND PROCEDURE:
Thirty subjects (forskolin, n = 15; placebo, n = 15) were studied in a randomized, double-blind, placebo-controlled study for 12 weeks.
RESULTS:
Forskolin was shown to elicit favorable changes in body composition by significantly decreasing body fat percentage (BF%) and fat mass (FM) as determined by DXA compared with the placebo group (p < or = 0.05). Additionally, forskolin administration resulted in a change in bone mass for the 12-week trial compared with the placebo group (p < or = 0.05). There was a trend toward a significant increase for lean body mass in the forskolin group compared with the placebo group (p = 0.097). Serum free testosterone levels were significantly increased in the forskolin group compared with the placebo group (p < or = 0.05). The actual change in serum total testosterone concentration was not significantly different among groups, but it increased 16.77 +/- 33.77% in the forskolin group compared with a decrease of 1.08 +/- 18.35% in the placebo group.
DISCUSSION:
Oral ingestion of forskolin (250 mg of 10% forskolin extract twice a day) for a 12-week period was shown to favorably alter body composition while concurrently increasing bone mass and serum free testosterone levels in overweight and obese men. The results indicate that forskolin is a possible therapeutic agent for the management and treatment of obesity.
Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women.
Henderson S,
Magu B,
Rasmussen C,
Lancaster S,
Kerksick C,
Smith P,
Melton C,
Cowan P,
Greenwood M,
Earnest C,
Almada A,
Milnor P,
Magrans T,
Bowden R,
Ounpraseuth S,
Thomas A,
Kreider RB.
Source
Exercise & Sport Nutrition Laboratory, Baylor University, Waco, TX.
Abstract
PURPOSE:
This study investigated the effects of Coleus Forskohlii (CF) on body composition, and determined the safety and efficacy of supplementation.
METHODS:
In a double blind and randomized manner, 23 females supplemented their diet with ForsLeantrade mark (250 mg of 10% CF extract, (n = 7) or a placebo [P] (n = 12) two times per day for 12-wks. Body composition (DEXA), body weight, and psychometric instruments were obtained at 0, 4, 8 & 12 weeks of supplementation. Fasting blood samples and dietary records (4-d) were obtained at 0 and 12-wks. Side effects were recorded on a weekly basis. Data were analyzed by repeated measures ANOVA and are presented as mean changes from baseline for the CF and placebo groups, respectively.
RESULTS:
No significant differences were observed in caloric or macronutrient intake. CF tended to mitigate gains in body mass (-0.7 +/- 1.8, 1.0 +/- 2.5 kg, p = 0.10) and scanned mass (-0.2 +/- 1.3, 1.7 +/- 2.9 kg, p = 0.08) with no significant differences in fat mass (-0.2 +/- 0.7, 1.1 +/- 2.3 kg, p = 0.16), fat free mass (-0.1 +/- 1.3, 0.6 +/- 1.2 kg, p = 0.21), or body fat (-0.2 +/- 1.0, 0.4 +/- 1.4%, p = 0.40). Subjects in the CF group tended to report less fatigue (p = 0.07), hunger (p = 0.02), and fullness (p = 0.04). No clinically significant interactions were seen in metabolic markers, blood lipids, muscle and liver enzymes, electrolytes, red cells, white cells, hormones (insulin, TSH, T3, and T4), heart rate, blood pressure, or weekly reports of side effects.
CONCLUSION:
Results suggest that CF does not appear to promote weight loss but may help mitigate weight gain in overweight females with apparently no clinically significant side effects.
Clinical efficacy of Coleus forskohlii (Willd.) Briq. (Makandi) in hypertension of geriatric population.
Jagtap M,
Chandola HM,
Ravishankar B.
Source
Lecturer, Department of Kayachikitsa, College of Ayurveda, Nigdi, Pune, Maharashtra, India.
Abstract
Hypertension is the most common psychosomatic disorder affecting 972 million people worldwide. The present clinical study deals with the effect of Makandi (Coleus forskohlii (Willd.) Briq.) Ghana vati and tablets of its powder in hypertension found in the geriatric age group (50-80 years). A total of 49 hypertensive patients fulfilling the diagnostic criteria were registered in two groups-Group I (Ghana vati) and Group II (Churna tablet). Out of 27 enrolled patients of group I, 21 patients completed the treatment. In Group II, out of 22 registered patients, a total of 20 patients completed the treatment. The effect of the therapy was assessed on the basis of changes in the systolic and diastolic blood pressures, in both sitting and supine positions; with Manasa Bhava Pariksha, Manasa Vibhrama Pariksha, symptomatology, geriatric signs and symptoms, and a brief psychiatric rating scale. Analysis of the results showed that the treatment in both the groups had been found to be good. It can be stated that Makandi, either in Ghana vati form or in churna tablet form, is an effective remedy for the treatment of hypertension. On analyzing the overall effect, 76.19% patients in Group I and 75.00% patients in Group II were mildly improved. Comparatively the overall treatment with group I was found to be better.
